Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AGN-210669 · 3 trials · 3 indications
IOP is a measurement of the fluid pressure inside the eye. The average of the 2 eyes are used for the analyses. A negative number change from baseline indicates a reduction in IOP (improvement) and a positive number change from baseline indicates an increase in IOP (worsening). Data are recorded at Hours 0, 4, 8, and 12.
IOP is a measurement of the fluid pressure inside the eye. The average of the 2 eyes is used for the analyses. A negative number change from baseline indicates a reduction in IOP (improvement) and a positive number change from baseline indicates an increase in IOP (worsening).
| Arm | Type | Description |
|---|---|---|
| AGN-210669 | EXPERIMENTAL | AGN-210669 0.05% applied as 1 drop in both eyes every evening during Month 1. |
| AGN-210669 + bimatoprost | EXPERIMENTAL | AGN-210669 0.05% + bimatoprost ophthalmic solution 0.03% applied as 1 drop of each treatment in both eyes every evening during Month 2. |
| AGN-210669 + bimatoprost vehicle | EXPERIMENTAL | AGN-210669 0.05% + bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop of each treatment in both eyes every evening during Month 2. |
| bimatoprost | ACTIVE_COMPARATOR | bimatoprost ophthalmic solution 0.03% applied as 1 drop in both eyes every evening during Month 1. |
| bimatoprost + AGN-210669 | EXPERIMENTAL | bimatoprost ophthalmic solution 0.03% + AGN-210669 0.05% applied as 1 drop of each treatment in both eyes every evening during Month 2. |
| bimatoprost + bimatoprost vehicle | OTHER | bimatoprost ophthalmic solution 0.03% + bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop of each treatment in both eyes every evening during Month 2. |
| AGN-210669 ophthalmic solution, 0.1% | EXPERIMENTAL | One drop of AGN-210669 ophthalmic solution, 0.1% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29. |
| AGN-210669 ophthalmic solution, 0.075% | EXPERIMENTAL | One drop of AGN-210669 ophthalmic solution, 0.075% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29. |
| AGN-210669 ophthalmic solution, 0.05% | EXPERIMENTAL | One drop of AGN-210669 ophthalmic solution, 0.05% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29. |
| bimatoprost ophthalmic solution 0.03% | ACTIVE_COMPARATOR | One drop of bimatoprost ophthalmic solution 0.03% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29. |
| AGN-210669 ophthalmic solution, 0.025% | EXPERIMENTAL | AGN-210669 non-preserved ophthalmic solution, 0.025%. One drop in both eyes each morning once-daily for 2 weeks. |
| AGN-210669 vehicle ophthalmic solution | PLACEBO_COMPARATOR | AGN-210669 vehicle non-preserved ophthalmic solution. One drop in both eyes each morning once-daily for 2 weeks. |
| Name | Type | Description |
|---|---|---|
| AGN-210669 | DRUG | AGN-210669 0.05% applied as 1 drop in both eyes every evening during Month 1 or Month 2. |
| bimatoprost | DRUG | bimatoprost ophthalmic solution 0.03% applied as 1 drop in both eyes every evening during Month 1 or Month 2. |
| bimatoprost vehicle | DRUG | bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop in both eyes every evening during Month 2. |
| AGN-210669 ophthalmic solution, 0.1% | DRUG | One drop of AGN-210669 ophthalmic solution, 0.1% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29. |
| AGN-210669 ophthalmic solution, 0.075% | DRUG | One drop of AGN-210669 ophthalmic solution, 0.075% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29. |
| AGN-210669 ophthalmic solution, 0.05% | DRUG | One drop of AGN-210669 ophthalmic solution, 0.05% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29. |
| bimatoprost ophthalmic solution 0.03% | DRUG | One drop of bimatoprost ophthalmic solution 0.03% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29. |
| AGN-210669 ophthalmic solution, 0.025% | DRUG | AGN-210669 non-preserved ophthalmic solution, 0.025%. One drop in both eyes each morning once-daily for 2 weeks. |
| AGN-210669 vehicle ophthalmic solution | DRUG | AGN-210669 vehicle non-preserved ophthalmic solution. One drop in both eyes each morning once-daily for 2 weeks. |
Inclusion Criteria: * Diagnosis of primary open-angle glaucoma or ocular hypertension in each eye * Requires bilateral treatment with an IOP-lowering medication * Best corrected visual acuity of 20/100 or better in each eye Exclusion Criteria: * Use of oral, intramuscular, intravenous or topical ...
AGN-210669, 0.075% is an investigational ophthalmic solution being studied for open-angle glaucoma and ocular hypertension. It is a small-molecule eye drop developed by AbbVie Inc. and has been evaluated in Phase 2 clinical trials in adults aged 18 years and older in the United States.
AGN-210669 is developed by AbbVie Inc., which trades on the New York Stock Exchange under the ticker ABBV. The compound is formulated as an ophthalmic solution in concentrations including 0.075% and 0.1% and has been studied in company-sponsored Phase 2 trials in the United States.
AGN-210669 is in Phase 2 development. It is an investigational product and is not approved for marketing. Two completed Phase 2 trials and one completed Phase 1/Phase 2 trial have evaluated the ophthalmic solution in patients with open-angle glaucoma or ocular hypertension.
AGN-210669 has been studied in completed trials including NCT01291108, which compared AGN-210669 ophthalmic solution with bimatoprost ophthalmic solution in 125 patients, and NCT01001195, which tested three formulations against bimatoprost in 165 patients. An earlier Phase 1/Phase 2 trial, NCT00809848, enrolled 172 patients.
Yes. AGN-210669, AGN-210669 ophthalmic solution, and the 0.075% and 0.1% concentrations all refer to the same investigational compound from AbbVie. The different names describe the drug substance and the strength of the eye drop formulation studied in glaucoma and ocular hypertension trials.
The AGN-210669 trials were randomized, double-blind, and active-controlled, using bimatoprost ophthalmic solution as the comparator. They enrolled adults 18 years and older with open-angle glaucoma or ocular hypertension, and together the completed studies involved 290 participants across the United States.